Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 10INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Pain 1Neoplasms 1Lymphoma, Follicular 1Alzheimer Disease 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Donepezil × Clear all
NCT00688376 2022-01-05

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

Eisai Inc.

Phase 3 Completed
72 enrolled 10 charts

Neoplasms, Pain

NCT00711204 2012-12-10

Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

Eisai Inc.

Phase 4 Withdrawn
Lymphoid

Alzheimer Disease, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡